Core Viewpoint - The company has entered into an exclusive licensing agreement with Madrigal Pharmaceuticals, Inc. for the global development, production, and commercialization of the oral small molecule GLP-1 receptor agonist SYH2086 [1] Group 1: Agreement Details - The agreement grants Madrigal exclusive rights to develop, produce, and commercialize SYH2086 globally while the company retains rights to develop and sell other oral small molecule GLP-1 receptor agonists in China [1] - The company is entitled to receive up to $2.075 billion in total consideration, which includes an upfront payment of $120 million and potential milestone payments of up to $1.955 billion based on development, regulatory, and commercial milestones [1] - Additionally, the company will receive a high double-digit sales royalty based on the annual net sales of SYH2086 [1]
石药集团与MADRIGAL就SYH2086订立独家授权协议